Complementary and Alternative Medicine Among Outpatients With Inflammatory Rheumatic Diseases in Western Sweden

This study has been completed.
Sponsor:
Information provided by:
Göteborg University
ClinicalTrials.gov Identifier:
NCT00665275
First received: April 18, 2008
Last updated: NA
Last verified: April 2008
History: No changes posted
  Purpose

This is an observational study aiming to study the use of complementary and alternative medicine (CAM) drugs and methods among patients with inflammatory rheumatic diseases, at Rheumatology clinics in western Sweden and also to investigate possible associations between CAM using habits and other characteristics of the patients.


Condition
Rheumatic Diseases

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Use of Complementary and Alternative Medicine Among Outpatients With Inflammatory Rheumatic Diseases in Western Sweden.

Further study details as provided by Göteborg University:

Primary Outcome Measures:
  • The prevalence of complementary and alternative medicine (CAM) drugs and methods among patients with inflammatory rheumatic diseases in western Sweden. [ Time Frame: July 2007 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To investigate potential significant associations between CAM using habits and characteristics of the patients. [ Time Frame: July 2007 ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Serum


Enrollment: 200
Study Start Date: March 2007
Study Completion Date: July 2007
Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)
Detailed Description:

Complementary and alternative medicine (CAM) is treatment that primarily is given outside the institutions where conventional medicine is practised. CAM drugs are substances that often have a natural origin and are taken orally or used topically, for self-treatment. CAM methods are therapies where the patient often goes to a practitioner, for example acupuncture, massage, homeopathy or chiropractics.

Most cultures have their own history of traditional treatments, with herbal medicine or spiritual healers.

The use of complementary and alternative medicine (CAM) is widespread and increasing in many countries. The sales figures in Sweden for CAM drugs, functional foods and dietary supplements have increased from 450 million to 4250 million SEK between 1980 and 2007. Many people of today use CAM as a complement, rather than an alternative, to conventional healthcare. Some alternative methods, like acupuncture and massage, have also been integrated into conventional medicine.

The biological effects of drugs containing herbs or animal parts are often unknown and there is a hazard of interaction with prescribed medication.

The use of CAM drugs is often not communicated by the patient to the physician. A Swedish point observation study of patients admitted to Sahlgrenska hospital 2004 showed that 69 % of the patients had used CAM drugs at any time in their life, but only 27,5% had informed their doctor about it. The use of CAM drugs was seldom documented in the medical records of the patient.

The utilization of CAM among patients with rheumatic diseases in Sweden has never been studied before.

The aim of this trial was to study the use of CAM methods and CAM drugs among patients seen at rheumatology practises in the west of Sweden. To investigate which methods and drugs that are being used and to see if there are connections between using habits and factors like gender, age, rheumatic diagnoses, disease activity, medication and the patients experience of pain, fatigue and general health. We were also interested in finding out the reason for use of CAM, and if the patients had experienced beneficial effects or side effects of the use.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Lists of outpatients who were scheduled for appointments at the rheumatology clinic were sent to an external randomizer, to randomly elect patients who were asked to participate. Patients were eligible for inclusion if they were attending the rheumatology clinic and had had an appointment there before. Patients were excluded if they were on their first visit to the practice, had dementia or had difficulties understanding Swedish.

Criteria

Inclusion Criteria:

  • Patients were eligible for inclusion if they were attending the rheumatology clinic and had had an appointment there before.

Exclusion Criteria:

  • Patients were excluded if they were on their first visit to the practice, had dementia or had difficulties understanding Swedish.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00665275

Locations
Sweden
Department of Rheumatology, Sahlgrenska University Hospital
Göteborg, Sweden, S-413 46
Sponsors and Collaborators
Göteborg University
Investigators
Principal Investigator: Helena Forsblad d'Elia, MD, PhD Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg
  More Information

No publications provided

Responsible Party: Helena Forsblad d'Elia, Department of Rheumatology and Inflammation Research
ClinicalTrials.gov Identifier: NCT00665275     History of Changes
Other Study ID Numbers: VGFOUREG-8462, VGFOUREG-12277
Study First Received: April 18, 2008
Last Updated: April 18, 2008
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Göteborg University:
complementary
alternative
medicine

Additional relevant MeSH terms:
Rheumatic Diseases
Musculoskeletal Diseases
Connective Tissue Diseases

ClinicalTrials.gov processed this record on August 19, 2014